Can-Fite BioPharma Dirección

Dirección controles de criterios 4/4

El CEO de Can-Fite BioPharma's es Motti Farbstein , nombrado en Aug 2003, tiene una permanencia de 20.67 años. compensación anual total es $467.00K, compuesta por 66.4% salario y 33.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0% de las acciones de la empresa, por valor de ₪31.14. La antigüedad media del equipo directivo y de la junta directiva es de 20.7 años y 15.7 años, respectivamente.

Información clave

Motti Farbstein

Chief Executive Officer (CEO)

US$467.0k

Compensación total

Porcentaje del salario del CEO	66.4%
Permanencia del CEO	20.8yrs
Participación del CEO	0.00008%
Permanencia media de la dirección	20.8yrs
Promedio de permanencia en la Junta Directiva	15.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Motti Farbstein en comparación con los beneficios de Can-Fite BioPharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$467k	US$310k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$471k	US$298k	-US$10m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$484k	US$291k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$468k	US$313k	-US$15m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$277k	US$195k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$331k	US$186k	-US$7m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$315k	US$242k	-US$6m

Compensación vs. Mercado: La compensación total ($USD467.00K) de Motti está en línea con el promedio de empresas de tamaño similar en el mercado IL ($USD432.00K).

Compensación vs. Ingresos: La compensación de Motti ha sido consistente con los resultados de la empresa en el último año.

CEO

Motti Farbstein (59 yo)

20.8yrs

Permanencia

US$467,000

Compensación

Mr. Motti Farbstein serves as a Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Executive Officer since June 30, 2023. Mr. Farbstein served as Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pnina Fishman	Founder	18.7yrs	US$703.00k	0.018% $ 6.9k
Motti Farbstein	CEO and Chief Financial & Operating Officer	20.8yrs	US$467.00k	0.000080% $ 31.1
Sari Fishman	Vice President of Business Development	10.3yrs	US$373.00k	sin datos
Ilan Cohn	Co-Founder & Director	29.7yrs	sin datos	0.0089% $ 3.5k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	less than a year	sin datos	sin datos

20.8yrs

Permanencia media

64yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CANF es experimentado (20.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pnina Fishman	Founder	18.7yrs	US$703.00k	0.018% $ 6.9k
Ilan Cohn	Co-Founder & Director	30.3yrs	sin datos	0.0089% $ 3.5k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	no data	sin datos	sin datos
Nabil Hanna	Member of Scientific Advisory Board	no data	sin datos	sin datos
Yaacov Goldman	External Independent Director	6.8yrs	US$60.00k	sin datos
Abraham Sartani	Independent Director	23.3yrs	sin datos	sin datos
Guy Regev	Independent External Director	12.8yrs	US$60.00k	0.0016% $ 630.6
Scott L. Friedman	Member of Clinical Advisory Board	no data	sin datos	sin datos
Arun Sanyal	Member of Clinical Advisory Board	no data	sin datos	sin datos
Yoseph Bornstein	Independent External Director	2.8yrs	sin datos	sin datos
Rifaat Safadi	Member of Clinical Advisory Board	no data	sin datos	sin datos
Kim Papp	Member of Clinical Advisory Board	no data	sin datos	sin datos

15.8yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de CANF son experimentados ( 15.7 años antigüedad media).

Can-Fite BioPharma Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Insufficient new directors

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Insufficient new directors

Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020

Recent updates

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020)

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

No longer forecast to breakeven

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. Provides Clinical Update

First quarter 2021 earnings released: US$0.004 loss per share (vs US$0.025 loss in 1Q 2020)

No longer forecast to breakeven

Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study

Full year 2020 earnings released: US$0.04 loss per share (vs US$0.11 loss in FY 2019)

Can-Fite BioPharma Ltd. Announces New Data from Preclinical Study of Its Drug Candidate CF602 in the Treatment of Erectile Dysfunction in Diabetes Experimental Model

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite Biopharma Ltd. Announces New Data from the Phase Ii Advanced Liver Cancer Study

New 90-day high: ₪0.31